MA29068B1 - Modulateurs heterocycliques a cycles fusionnes pour les kinases - Google Patents

Modulateurs heterocycliques a cycles fusionnes pour les kinases

Info

Publication number
MA29068B1
MA29068B1 MA29694A MA29694A MA29068B1 MA 29068 B1 MA29068 B1 MA 29068B1 MA 29694 A MA29694 A MA 29694A MA 29694 A MA29694 A MA 29694A MA 29068 B1 MA29068 B1 MA 29068B1
Authority
MA
Morocco
Prior art keywords
kinases
heterocyclic modulators
fused cycles
fused
cycles
Prior art date
Application number
MA29694A
Other languages
English (en)
Inventor
William D Arnold
Andreas Gosberg
Zhe Li
Ruo W Steensma
Mark E Wilson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of MA29068B1 publication Critical patent/MA29068B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA29694A 2004-07-27 2007-02-21 Modulateurs heterocycliques a cycles fusionnes pour les kinases MA29068B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59177804P 2004-07-27 2004-07-27
US59188604P 2004-07-27 2004-07-27
US68009105P 2005-05-11 2005-05-11

Publications (1)

Publication Number Publication Date
MA29068B1 true MA29068B1 (fr) 2007-12-03

Family

ID=35512008

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29694A MA29068B1 (fr) 2004-07-27 2007-02-21 Modulateurs heterocycliques a cycles fusionnes pour les kinases

Country Status (15)

Country Link
US (2) US7452993B2 (fr)
EP (2) EP1778687A2 (fr)
JP (1) JP2008508304A (fr)
KR (1) KR20070053236A (fr)
AU (1) AU2005269387A1 (fr)
BR (1) BRPI0513899A (fr)
CA (1) CA2573573A1 (fr)
EC (1) ECSP077273A (fr)
IL (1) IL180676A0 (fr)
MA (1) MA29068B1 (fr)
MX (1) MX2007001126A (fr)
NO (1) NO20070908L (fr)
SG (1) SG156685A1 (fr)
TN (1) TNSN07028A1 (fr)
WO (1) WO2006015124A2 (fr)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
KR20070053237A (ko) 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 피롤로-피리딘 키나제 조절제
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1814882A1 (fr) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
NZ563444A (en) * 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
JP2009515984A (ja) 2005-11-15 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアザインダゾール
US20130096302A1 (en) * 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US9534001B2 (en) * 2006-03-03 2017-01-03 Chemetall Gmbh Organomagnesium synthesis agent
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
KR20090071612A (ko) * 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (fr) * 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
US8242280B2 (en) * 2007-04-10 2012-08-14 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008254588B2 (en) * 2007-05-21 2013-01-17 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
EP2157090A4 (fr) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd Composé de pyrazinamide
US20100210644A1 (en) * 2007-06-25 2010-08-19 Boehringer Ingelheim International Gmbh Chemical compounds
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
PL2247592T3 (pl) * 2008-02-25 2012-01-31 Hoffmann La Roche Pirolopirazynowe inhibitory kinazy
EP2247595B1 (fr) * 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Inhibiteurs de kinase pyrrolopyrazine
ES2372908T3 (es) * 2008-02-25 2012-01-27 F. Hoffmann-La Roche Ag Inhibidores de la pirrolopirazina quinasa.
CN102131811A (zh) * 2008-06-24 2011-07-20 财团法人乙卯研究所 具有稠合环的*唑烷酮衍生物
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
EP2376485B1 (fr) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Dérivés pyrazines utiles en tant qu'inhibiteurs d'atr kinase
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CA2770320A1 (fr) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/beta-catenine et utilisations therapeutiques de ceux-ci
DK2987487T3 (da) 2009-08-10 2020-12-07 Samumed Llc Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
EP2470533A4 (fr) 2009-08-24 2013-01-23 Ascepion Pharmaceuticals Inc Composés d'urée contenant un groupe hétéroaryle 5,6-bicyclique
MA33975B1 (fr) 2009-11-06 2013-02-01 Plexxikon Inc Composés et méthodes de modulation des kinases et leurs indications d'emploi
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
CN102858769A (zh) * 2010-01-27 2013-01-02 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
MX2012008642A (es) * 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
WO2011109593A1 (fr) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC 5-aminopyrrolo/pyrazolopyridines substituées
AU2011253021A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2568984A1 (fr) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de l'atr kinase
EP2569286B1 (fr) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Composés utilisables en tant qu'inhibiteurs de la kinase atr
KR20130066633A (ko) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143646A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
MX2013000103A (es) * 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
JP2014510151A (ja) 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物
EP2710003A1 (fr) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
WO2012178123A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
EP2723746A1 (fr) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Composés inhibiteurs de la kinase atr
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP3473099A1 (fr) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation par wnt/b-caténine
KR102056586B1 (ko) 2011-09-30 2019-12-18 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료
EP2751099B1 (fr) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
WO2013049720A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase atr
BR112014007721B1 (pt) 2011-09-30 2022-11-01 Vertex Pharmaceuticals Incorporated Processos para preparar compostos úteis como inibidores de atr quinase
WO2013049719A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase atr
WO2013071094A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
WO2013071093A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés de pyrazine utiles comme inhibiteurs de kinase atr
EP2776421A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
CA2860382C (fr) 2011-12-21 2017-09-12 Allergan, Inc. Composes ayant un effet sur de multiples recepteurs des prostaglandines et permettant d'obtenir une reponse anti-inflammatoire generale
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
KR102223301B1 (ko) 2012-05-04 2021-03-05 사뮤메드, 엘엘씨 1H-피라졸로[3,4-b]피리딘 및 그의 치료 용도
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2015004615A (es) * 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US9908867B2 (en) 2013-01-08 2018-03-06 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
WO2014143240A1 (fr) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
MX2016002626A (es) 2013-08-30 2016-06-06 Ambit Biosciences Corp Compuestos de biarilacetamida y metodos de uso de los mismos.
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
CN103980272B (zh) * 2014-04-18 2016-02-17 海门瑞一医药科技有限公司 一种合成5-氰基-1H-吡唑并[3,4-b]吡啶的方法
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
WO2016040185A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
WO2016040184A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040193A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040181A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040182A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
WO2016040190A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040180A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040188A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016164641A1 (fr) * 2015-04-08 2016-10-13 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications
CA2992945A1 (fr) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Therapie combinee utilisant des inhibiteurs de pdk1 et de pi3k
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023986A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
WO2017023972A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017023989A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024015A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
WO2017023987A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20170129902A1 (en) 2015-10-16 2017-05-11 Abbvie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017079759A1 (fr) 2015-11-06 2017-05-11 Samumed, Llc 2-(3h-indazol-3-yl)-1h-imidazo[4,5-c]pyridines et leurs utilisations anti-inflammatoires
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
SG10201912248RA (en) 2016-06-01 2020-02-27 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
AU2017345699A1 (en) 2016-10-21 2019-05-16 Samumed, Llc Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors
WO2018085865A1 (fr) 2016-11-07 2018-05-11 Samumed, Llc Formulations injectables à dose unique prêtes à l'emploi
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
MA51846A (fr) 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
KR102108414B1 (ko) * 2018-11-21 2020-05-11 중앙대학교 산학협력단 Aurka 매개 kdm6b 활성 조절을 통한 암세포 분화 조절 용도
TWI848141B (zh) * 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
TW202116771A (zh) 2019-07-17 2021-05-01 英屬開曼群島商百濟神州有限公司 作為ｈｐｋ１抑制劑之三環化合物及其用途
US20220281859A1 (en) * 2019-08-14 2022-09-08 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN113429408A (zh) * 2021-07-07 2021-09-24 南方科技大学 含氮杂环化合物及其制备方法、药物组合物和应用
CN118834206A (zh) * 2023-04-24 2024-10-25 北京宇繁科技有限责任公司 一种map4k4抑制剂及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
US5019586A (en) * 1987-04-14 1991-05-28 Glaxo Group Limited Ketone derivatives
MX19185A (es) * 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB2298199A (en) * 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
AU5645196A (en) 1995-04-11 1996-10-30 Lonza A.G. Process for preparing azaindoles with an activated copper ch romite catalyst by catalytic dehydrocyclisation of alkylpyri dylamines (pyridopyridines)
WO2000024694A1 (fr) * 1998-10-28 2000-05-04 Eli Lilly And Company Procede photochimique pour l'obtention de derives 1-desoxy-2-ceto
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
DE19955915C2 (de) 1999-11-20 2001-09-13 Wella Ag Tryptophanderivate und Tryptophanase enthaltende Haarfärbemittel sowie Verfahren zur enzymatischen Haarfärbung
DE10053122A1 (de) 1999-11-20 2001-05-23 Wella Ag Verfahren zur Herstellung von Indolen sowie die Verwendung dieser Indole in Färbemitteln
DE19959122A1 (de) 1999-12-02 2001-06-07 Spree Chemie Gmbh Handreiniger
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002024694A1 (fr) 2000-09-22 2002-03-28 Smithkline Beecham, P.L.C. Pyrazolopyridines et pyrazolopyridazines utilisees comme antidiabetiques
CN1281605C (zh) 2000-12-22 2006-10-25 惠氏公司 作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
CA2440842A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazoles
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003028724A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de la kinase chk1
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2003068773A1 (fr) 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
IL164082A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd Azaindole derivatives and pharmaceutical compositions containing the same
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
TW200406385A (en) * 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
CA2495216A1 (fr) * 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
AU2003272548A1 (en) 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
FR2845382A1 (fr) * 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
CN1713910A (zh) 2002-10-09 2005-12-28 西奥斯股份有限公司 作为p38激酶抑制剂的氮杂吲哚衍生物
JP2006517966A (ja) * 2003-02-14 2006-08-03 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004078756A2 (fr) 2003-03-06 2004-09-16 Eisai Co., Ltd. Inhibiteurs des jun-kinases (jnk)
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
PT1730146E (pt) 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
KR20070053237A (ko) 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 피롤로-피리딘 키나제 조절제
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101218241B (zh) 2005-05-16 2011-02-16 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物

Also Published As

Publication number Publication date
SG156685A1 (en) 2009-11-26
MX2007001126A (es) 2007-09-25
IL180676A0 (en) 2007-06-03
BRPI0513899A (pt) 2008-05-20
KR20070053236A (ko) 2007-05-23
US7829558B2 (en) 2010-11-09
EP1778687A2 (fr) 2007-05-02
AU2005269387A1 (en) 2006-02-09
WO2006015124A3 (fr) 2006-10-05
ECSP077273A (es) 2007-03-29
EP2239262A3 (fr) 2011-10-19
JP2008508304A (ja) 2008-03-21
WO2006015124A2 (fr) 2006-02-09
NO20070908L (no) 2007-03-14
EP2239262A2 (fr) 2010-10-13
TNSN07028A1 (en) 2008-06-02
US20090203687A1 (en) 2009-08-13
CA2573573A1 (fr) 2006-02-09
US7452993B2 (en) 2008-11-18
US20060035898A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
MA29068B1 (fr) Modulateurs heterocycliques a cycles fusionnes pour les kinases
IL190280A0 (en) Fused heterocyclic compounds useful as kinase modulators
MA28463B1 (fr) Derives de 4-oxopyrimidine a cycles fusionnes
IL180325A0 (en) Fused heterocyclic kinase inhibitors
IL186407A0 (en) Fused heterocyclic compounds
IL179414A0 (en) Fused heterocyclic compound
SI1668014T1 (sl) Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
EP2134179A4 (fr) Modulateurs de kinase hétérocyclique à cycles fusionnés
EP2078020A4 (fr) Modulateurs hétérocycliques à cycles fusionnés pour les kinases
ATE399495T1 (de) Kapsel mit dichtungsmitteln
IL194815A0 (en) Fused heterocyclic compounds and their use as mglur5 modulators
EP2162132A4 (fr) Modulateurs de kinase hétérocycliques
NO20071302L (no) Bindingdomene fusjonsproteiner
FR2864763B1 (fr) Prothese discale pour vertebres
DE602005000450D1 (de) Naher Fluidmeniskusverteiler
EP1830086A4 (fr) Structure de joint pour element de rotation
DK1948607T3 (da) Cyclopropylaminer med histamin-H3-receptormodulatorer
EP1840442A4 (fr) Element de joint pour joint de tuyau
EP1737446A4 (fr) Composes heterocycliques fusionnes
ZA200610780B (en) Fused heterocyclic kinase inhibitors
ZA200802549B (en) Fused heterocyclic compounds useful as kinase modulators
DE602005001543D1 (de) Füllorgan mit ersetzbaren Ausläufen
EP1812361A4 (fr) Matériaux pour des surfaces praticables
EP2070927A4 (fr) Dérivé hétérocyclique fusionné
FR2892568B1 (fr) Raccord pour element de contact